Battle? Won. War? Still Being Fought | GenomeWeb

Myriad Genetics won a significant victory last month when an appeals court upheld the company's gene patents. But now, The New York Times' Andrew Pollack says, the real battle starts for Myriad. Some experts say the company's test for the BRCA1 and BRCA2 mutations is "technologically outmoded, incomplete and too costly," Pollack reports.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.